drugset / Trial / NCT01834079

Study the Safety and Efficacy of Bone Marrow Derived Autologous Cells for the Treatment of Optic Nerve Disease

NCT01834079

Phase 1/2 Unknown 24 enrolled Chaitanya Hospital, Pune
NaSingle-groupOpen-labelTreatment

Summary

This is a Single arm, Single centre trial to check the safety and efficacy of bone marrow derived autologous mono nuclear cell(100 millions per dose )clinical trial to be conducted for 36 months in patients with optic nerve diseases.

Timeline

Start
2014-09
Primary completion
2016-07
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Autologous Stem Cells Cell therapy 1e+08 cells Intrathecal

Indications